Opposite effects of CCK(B) agonists in grooming behaviour in rats: Further evidence for two CCK(B) subsites

British Journal of Pharmacology

Volumn 124, Issue 6, 1998, Pages 1091-1098

  Ladurelle, Nathalie ^a   Sebret, Angélique ^a   Garbay, Christiane ^a   Roques, Bernard P ^a   Daugé, Valérie ^a  

^a FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

Author keywords

BC197; BC264; CCK(B) receptor subsites; Dopamine; Grooming activity

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; BC 197; BC 264; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; RECEPTOR SUBUNIT; SULPIRIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; GROOMING; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

EID: 0031874680     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701933     Document Type: Article

References (43)

1. BRADWEJN, J., KOSZYCKI, D., COUËTOUX DU TERTRE, A., VAN MEGEN, H., DEN BOER, J., WERTENBERG, H. & ANNABLE, L. (1994). The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist in patients with panic disorder. Arch. Gen. Psychiat., 51, 486-493.
2. CHARRIER, D., DANGOUMOU, L., PUECH, A.J., HAMON, M. & THIEBOT, M-H. (1995). Failure of CCK receptor ligands to modify anxiety-related behavioral suppression in an operant conflict paradigm in rats. Psychopharmacology, 121, 127-134.
3. CHARPENTIER, B., DURIEUX, C., PELAPRAT, D., DOR, A., REIBAUD, M., BLANCHARD, J.C. & ROQUES, B.P. (1988a). Enzyme resistant CCK analogs with high affinities for central receptors. Peptides, 9, 835-841.
4. CHARPENTIER, B., PELAPRAT, D., DURIEUX, C., DOR, A., REIBAUD, M., BLANCHARD, J.C. & ROQUES, B.P. (1988b). Cyclic cholecystokinin analogues with high selectivity for central receptors. Proc. Natl. Acad. Sci. U.S.A., 85, 1968-1972.
5. COLBERN, D.L. & GISPEN, W.H. (ed.). (1988) Neural mechanisms and biological significance of grooming behavior. Ann. New York Acad. Sci., 525.
6. COSTALL, B., DOMENEY, A.M., HUGHES, J , KELLY, M.E., NAYLOR, R.J. & WOODRUFF, G.N (1991). Anxiolytic effects of CCK-B antagonists. Neuropeptides, 19 (suppl.), 65-73.
7. CRAWLEY, J.N. (1991). Cholecystokinin-dopamine interactions. Trends Pharmacol. Sci., 12, 232-236.
8. CRAWLEY, J.N. & CORWIN, R.L. (1994). Biological actions of cholecystokinin. Peptides, 15, 731-755.
9. DAUGÉ, V., DERRIEN, M., BLANCHARD, J.C. & ROQUES, B.P. (1992). The selective CCK-B agonist BC264 injected in the anterolateral part of the nucleus accumbens reduces the spontaneous alternation behaviour of rats. Neuropharmacology, 31, 67-75.
10. DAUGÉ, V. & ROQUES, B.P. (1995). Reward and anxiety: The opposite pharmacology of opioids and CCK. In Cholecystokinin and Anxiety, from Neuron to Behavior. Bradwejn, J. & Vasar, E. ed. pp. 161-171. R.G. Landes Company.
11. DERRIEN, M., McCORT-TRANCHEPAIN, I., DUCOS, B., ROQUES, B.P. & DURIEUX, C. (1994) Heterogeneity of CCK-B receptors involved in animals models of anxiety. Pharmacol. Biochem. Behav., 49, 133-141.
12. DIAMOND, B.I., PASINETTI, G., HITRI, A. & BORISON, R.L (1984). Extrapyramidal dopamine regulation by cholecystokinin and its role in Parkinson's disease. Adv. Neurology, 40, 483-488.
13. DURIEUX, C., COPPEY, M., ZAJAC, J.M. & ROQUES, B.P (1986). Occurence of two cholecystokinin binding sites in guinea pig cortex. Biochem. Biophys. Res. Commun. 137, 1167-1173.
14. 3H]-CCK4 binding sites in mouse and rat brain. Neuropeptides. 12, 141-148.
15. 3H]-pentagastrin. Peptides, 4, 755-762.
16. HARPER, E.A., ROBERTS, S.P., SHANKLEY, N.P. & BLACK, J.W. (1996). Analysis of variation in L-365,260 competition curves in radioligand binding assays. Br. J. Pharmacol., 118, 1717-1726.
17. HARRO, J., VASAR, E. & BRADWEJN, J. (1993). CCK in animal and human research on anxiety. Trends Pharmacol. Sci., 14, 244-249.
18. HILL, D.R., CAMPBELL, N.J., SHAW, T.M & WOODRUFF, G.M. (1987). Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide CCK antagonists. J. Neurosci., 7, 2967-2976.
19. HÖKFELT, T., REHFELD, J.F., SKIRBOLL, L., IVEMARK, B., GOLDSTEIN, M. & MARKEY, K. (1980). Evidence for coexistence of dopamine and CCK in mesolimbic neurons. Nature, 285, 476-478.
20. HUANG, S.C., FORTUNE, K.P., WANK, S.A., KOPIN, A.S. & GARDNER, D. (1994). Multiple affinity states of cholecystokinin receptors. Biol. Chem., 269, 26121-26126.
21. HUGHES, J., BODEN, P., COSTALL, B., DOMENEY, A , KELLY, E., HORWELL, D.C., HUNTER, J.C., PINNOCK, R.D. & WOODRUFF, G.N. (1990). Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc. Natl. Acad. Sci. U.S.A., 87, 6728-6732.
22. 3H][N-methyl-Nle28,31]CCK26-33): Evidence for CCK-B receptor heterogeneity. J. Pharmacol. Exp. Ther., 255, 1278-1286.
23. KULKOSKY, P.J. (1988). Bombesin and ceruletide-induced grooming and inhibition of ingestion in the rat. Ann. New York Acad. Sci., 525, 201-218.
24. LADURELLE, N., KELLER, G., BLOMMAERT, A , ROQUES, B.P. & DAUGE, V. (1997). The CCK-B agonist BC264 increases dopamine in the nucleus accumbens and facilitates motivation and attention after intraperitoneal injection in rats. Eur. J. Neurosci., 9, 1804-1814.
25. LEE, Y.M., BEINBORN, M., McBRIDE, E.W. LU, M., KOLAKOWSKI, L.F. & KOPIN, A.S. Jr. (1993). The human brain cholecystokinin-B/gastrin receptor. J. Biol. Chem., 268, 8164-8169.
26. LEFF, P., SCARAMELLINI, C., LAW, C. & MCKECHNIE, K. (1997). A three-state receptor model of agonist action. Trends Pharmacol. Sci., 18, 355-362.
27. LÉNA, I., ROQUES, B.P. & DURIEUX, C. (1997). Dual modulation of dopamine release from anterior nucleus accumbens through CCK-B receptor subsites. J. Neurochem., 68, 162-168.
28. LOTTI, V.J. & CHANG, R.S.L. (1989). A new potent and selective non peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365, 260. Eur. J. Pharmacol., 162, 273-280.
29. MAZURKI, E.J. & BENINGER, R.J. (1991). Effects of selective drugs for dopaminergic D1 and D2 receptors on conditioned locomotion in rats. Psychopharmacology, 105, 107-112.
30. MOLLOY, A.G. & WADDINGTON, J.L. (1984). Dopaminergic behavior stereospecifically promoted by the D1 agonist SKF 38393 and selectively blocked by the D1 antagonist SCH 23390. Psychopharmacology, 82, 409-410.
31. MOODY, T.W., MERALI, Z & CRAWLEY, J.N. (1988) The effects of anxiolytics and other agents on rat grooming behavior. Ann. New York Acad. Sci., 525, 281-290.
32. MORAN, T.H., ROBINSON, P.H., GOLDRICH, M.S. & McHUNGH, P.R. (1986). Two brain cholecystokinin receptors: Implications for behavioral actions. Brain Res. 362, 175-179.
33. 125I) Bolton-Hunter CCK8. Functional significance of subregional distributions. Neurochem. Int., 10, 495-508.
34. PEREZ, D.M., HWA, J., GAIVIN, R., MATHUR, M., BROWN, F. & GRAHAM, R.M. (1996). Constitutive activation of a single effector pathway: Evidence for multiple activation states of G protein-coupled receptors. Mol. Pharmacol., 49, 112-122.
35. RATAUD, J., DARCHE, F., PIOT, O., STUTZMANN, JM., BÖHME, G.A. & BLANCHARD, J.C. (1991). "Anxiolytic" effect of CCK-antagonists on plus maze behavior in mice. Brain Res. 548, 315-317.
36. REX, A., FINK, H. & MARSDEN, C.A. (1994). Effects of Boc-CCK4 and L-365,260 on cortical 5-HT release in guinea-pigs on exposure to the elevated plus maze. Neuropharmacology, 33, 559-565.
37. RICHMOND, G. & SACHS, B.D. (1980). Grooming in Norway rats: The development and adult expression of a complex motor pattern. Behavior, 75, 82-96.
38. pBC264: evidence for a physiological regulation of CCKergic systems by endogenous enkephalins. J. Neurochem., 59, 1805-1811.
39. SAMPSON, D., WILLNER, P. & MUSCAT, R. (1991). Reversal of antidepressant action by dopamine antagonists in an animal model of depression. Psychopharmacology, 104, 491-495.
40. SINGH, E., LEWIS, A.J.,FIELD, M.J., HUGHES, J. & WOODRUFF, G.N. (1991). Evidence for an involvement of brain cholecystokinin B receptor in anxiety. Proc. Natl. Acad. Sci. U.S.A., 88, 1130-1133.
41. STARR, B.S. & STARR, M.S. (1986). Differential effects of dopamine D1 and D2 agonists and antagonists on velocity of movement, rearing and grooming in the mouse. Implication for the roles of D1 and D2 receptors. Neuropharmacology, 25, 455-463.
42. TALKAD, V.D., FORTUNE, K.P., POLLO, D.A., SHAH, G.N., WANK, S.A. & GARDNER, J.D. (1994). Direct demonstration of three different states of the pancreatic cholecystokinin receptor. Proc. Natl. Acad. Sci. U.S.A., 91, 1868-1872.
43. WANK, S.A., PISEGNA, J.R. & DE WEERTH, A. (1992). Brain and gastrointestinal cholecystokinin receptor family: Structure and functional expression. Proc. Natl. Acad. Sci. U.S.A., 89, 8691-8695.